SE9101709L - Lipidderivat som diagnostikum eller kontrastmedel - Google Patents

Lipidderivat som diagnostikum eller kontrastmedel

Info

Publication number
SE9101709L
SE9101709L SE9101709A SE9101709A SE9101709L SE 9101709 L SE9101709 L SE 9101709L SE 9101709 A SE9101709 A SE 9101709A SE 9101709 A SE9101709 A SE 9101709A SE 9101709 L SE9101709 L SE 9101709L
Authority
SE
Sweden
Prior art keywords
pct
diagnostic
contractant
lipid derivatives
date dec
Prior art date
Application number
SE9101709A
Other languages
Unknown language ( )
English (en)
Swedish (sv)
Other versions
SE9101709D0 (sv
Inventor
B Hersloev
K Larsson
S Bengmark
Original Assignee
Karlshamns Lipidteknik Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karlshamns Lipidteknik Ab filed Critical Karlshamns Lipidteknik Ab
Priority to SE9101709A priority Critical patent/SE9101709L/
Publication of SE9101709D0 publication Critical patent/SE9101709D0/xx
Priority to DK92911840T priority patent/DK0588869T3/da
Priority to EP92911840A priority patent/EP0588869B1/en
Priority to CA002103462A priority patent/CA2103462C/en
Priority to AT92911840T priority patent/ATE185490T1/de
Priority to ES92911840T priority patent/ES2140409T3/es
Priority to AU19033/92A priority patent/AU652260B2/en
Priority to DE69230144T priority patent/DE69230144T2/de
Priority to PCT/SE1992/000374 priority patent/WO1992021384A1/en
Priority to US08/157,048 priority patent/US5550263A/en
Priority to JP04510824A priority patent/JP3013939B2/ja
Publication of SE9101709L publication Critical patent/SE9101709L/
Priority to FI935386A priority patent/FI935386A0/fi
Priority to NO934383A priority patent/NO308126B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0438—Organic X-ray contrast-enhancing agent comprising an iodinated group or an iodine atom, e.g. iopamidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0461—Dispersions, colloids, emulsions or suspensions
    • A61K49/0466—Liposomes, lipoprotein vesicles, e.g. HDL or LDL lipoproteins, phospholipidic or polymeric micelles
SE9101709A 1991-06-03 1991-06-03 Lipidderivat som diagnostikum eller kontrastmedel SE9101709L (sv)

Priority Applications (13)

Application Number Priority Date Filing Date Title
SE9101709A SE9101709L (sv) 1991-06-03 1991-06-03 Lipidderivat som diagnostikum eller kontrastmedel
JP04510824A JP3013939B2 (ja) 1991-06-03 1992-06-03 Ｘ線造影剤
AU19033/92A AU652260B2 (en) 1991-06-03 1992-06-03 X-ray contrast agent
EP92911840A EP0588869B1 (en) 1991-06-03 1992-06-03 X-ray contrast agent
CA002103462A CA2103462C (en) 1991-06-03 1992-06-03 X-ray contrast agent
AT92911840T ATE185490T1 (de) 1991-06-03 1992-06-03 Röntgenkontrastmittel
ES92911840T ES2140409T3 (es) 1991-06-03 1992-06-03 Agente de contraste para rayos x.
DK92911840T DK0588869T3 (da) 1991-06-03 1992-06-03 Røntgenkontrastmiddel
DE69230144T DE69230144T2 (de) 1991-06-03 1992-06-03 Röntgenkontrastmittel
PCT/SE1992/000374 WO1992021384A1 (en) 1991-06-03 1992-06-03 X-ray contrast agent
US08/157,048 US5550263A (en) 1991-06-03 1992-06-03 X-ray contrast agent
FI935386A FI935386A0 (fi) 1991-06-03 1993-12-01 Roentgenkontrastmedel
NO934383A NO308126B1 (no) 1991-06-03 1993-12-02 Fosfolipidbasert forbindelse, anvendelse derav samt røntgenkontrastmiddel

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9101709A SE9101709L (sv) 1991-06-03 1991-06-03 Lipidderivat som diagnostikum eller kontrastmedel

Publications (2)

Publication Number Publication Date
SE9101709D0 SE9101709D0 (sv) 1991-06-03
SE9101709L true SE9101709L (sv) 1992-12-04

Family

ID=20382938

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9101709A SE9101709L (sv) 1991-06-03 1991-06-03 Lipidderivat som diagnostikum eller kontrastmedel

Country Status (13)

Country Link
US (1) US5550263A (no)
EP (1) EP0588869B1 (no)
JP (1) JP3013939B2 (no)
AT (1) ATE185490T1 (no)
AU (1) AU652260B2 (no)
CA (1) CA2103462C (no)
DE (1) DE69230144T2 (no)
DK (1) DK0588869T3 (no)
ES (1) ES2140409T3 (no)
FI (1) FI935386A0 (no)
NO (1) NO308126B1 (no)
SE (1) SE9101709L (no)
WO (1) WO1992021384A1 (no)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE470086B (sv) * 1991-04-23 1993-11-08 Kabi Pharmacia Ab Organspecifik emulsion
US6217849B1 (en) * 1993-09-29 2001-04-17 Bracco Research S.A. Liposome suspensions as blood pool imaging contrast agents
US5851510A (en) * 1994-05-16 1998-12-22 The Board Of Regents Of The University Of Michigan Hepatocyte-selective oil-in-water emulsion
GB9420390D0 (en) * 1994-10-10 1994-11-23 Nycomed Salutar Inc Liposomal agents
WO2001082977A1 (fr) * 2000-04-28 2001-11-08 Fuji Photo Film Co., Ltd. Liposomes contenant un compose iodo hydrophobe
US7008614B2 (en) * 2001-08-20 2006-03-07 Fuji Photo Film Co., Ltd. Liposome containing hydrophobic iodine compound and X-ray contrast medium for radiograph comprising the liposome
US20040018237A1 (en) 2002-05-31 2004-01-29 Perricone Nicholas V. Topical drug delivery using phosphatidylcholine
US7498018B2 (en) * 2003-10-03 2009-03-03 Bracco Diagnostics Inc. Contrast media for use in medical and diagnostic procedures and methods of using the same
DE102004049652A1 (de) * 2004-10-11 2006-04-20 Degussa Ag Leitungssystem für Fluide und Gase in einer Brennstoffzelle
WO2007129311A2 (en) * 2006-05-04 2007-11-15 Pan Sci Tech S.A. Nano-particles with contrast agents for diagnostic delivery system for x-ray and ct
CN103547258B (zh) 2011-03-17 2017-10-20 特兰斯德梅尔生物工艺股份有限公司 局部一氧化氮系统及其使用方法
EP2532649B1 (en) * 2011-06-07 2015-04-08 Incella GmbH Amino lipids, their synthesis and uses thereof
WO2013121284A1 (en) * 2012-02-14 2013-08-22 Universite De Strasbourg Iodinated products intended for a use for the medical imaging and their methods of preparation
US8871260B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and compositions for muscular and neuromuscular diseases
US8871261B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Cancer treatments and compositions for use thereof
US8871258B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment and prevention of learning and memory disorders
US8871254B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system
US8871262B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Compositions and methods for treatment of osteoporosis and other indications
US8871255B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment of skin and soft tissue infection with nitric oxide
US8871256B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and systems for treatment of inflammatory diseases with nitric oxide
US8871259B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Techniques and systems for treatment of neuropathic pain and other indications
US8871257B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery
US9393264B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9314417B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9849160B2 (en) 2013-03-13 2017-12-26 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9393265B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9295637B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US9339457B2 (en) 2013-03-13 2016-05-17 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9387159B2 (en) 2013-03-13 2016-07-12 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US20140271938A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US20140271937A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9314422B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9724419B2 (en) 2013-03-13 2017-08-08 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9314423B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US9687520B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9241899B2 (en) 2013-03-13 2016-01-26 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US9295647B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9320758B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9320706B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9314433B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US20140271731A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9750787B2 (en) 2013-03-13 2017-09-05 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9295636B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
EP2968619B1 (en) * 2013-03-15 2021-08-11 The Regents of the University of California Enteric ct contrast material based on low-z atoms

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235792A (en) * 1977-04-14 1980-11-25 The Governing Council Of The University Of Toronto Immunological materials
US4192859A (en) * 1978-09-29 1980-03-11 E. R. Squibb & Sons, Inc. Contrast media containing liposomes as carriers
CH641682A5 (en) * 1978-10-05 1984-03-15 Daeniker Felix X-ray contrast medium
US4386078A (en) * 1980-03-03 1983-05-31 The Ohio State University Research Foundation Therapeutic agents for preventing phospholipid degradation and free fatty acid proliferation
US4480041A (en) * 1982-07-09 1984-10-30 Collaborative Research, Inc. Use of phosphotriester intermediates for preparation of functionalized liposomes
JPS59187792A (ja) * 1983-04-11 1984-10-24 Meito Sangyo Kk 酵素法リン脂質糖類誘導体の製法
DE3778626D1 (de) * 1986-09-27 1992-06-04 Toyo Jozo Kk Nukleosid-phospholipid-konjugat.
JPS63233374A (ja) * 1987-03-20 1988-09-29 Tohoku Denshi Sangyo Kk 過酸化脂質の測定方法およびその測定装置
CH672733A5 (no) * 1987-05-22 1989-12-29 Bracco Ind Chimica Spa
CA1340413C (en) * 1987-09-09 1999-03-02 Chiron Diagnostics Corporation Method of preparing phosphodiester conjugates useful for immunoactive liposomes

Also Published As

Publication number Publication date
CA2103462A1 (en) 1992-12-04
JP3013939B2 (ja) 2000-02-28
DK0588869T3 (da) 2000-04-17
DE69230144T2 (de) 2000-05-25
JPH06510276A (ja) 1994-11-17
NO308126B1 (no) 2000-07-31
NO934383D0 (no) 1993-12-02
AU652260B2 (en) 1994-08-18
EP0588869B1 (en) 1999-10-13
EP0588869A1 (en) 1994-03-30
ES2140409T3 (es) 2000-03-01
WO1992021384A1 (en) 1992-12-10
SE9101709D0 (sv) 1991-06-03
FI935386A (fi) 1993-12-01
ATE185490T1 (de) 1999-10-15
CA2103462C (en) 1998-03-31
NO934383L (no) 1993-12-02
US5550263A (en) 1996-08-27
DE69230144D1 (de) 1999-11-18
FI935386A0 (fi) 1993-12-01
AU1903392A (en) 1993-01-08

Similar Documents

Publication Publication Date Title
SE9101709L (sv) Lipidderivat som diagnostikum eller kontrastmedel
NO961377L (no) Distamycin A-analoger som antitumor eller antivirale midler
ATE191334T1 (de) Hydrophilierte zahnabdruckmassen
ITMI921601A1 (it) Uso di nor- e omo-derivati di acidi biliari come promotori di assorbimento di farmaci.
NO912630L (no) Fremgangsmaate for fremstilling av nye 2,6-dialkyl-4-silyl-fenoler som antiarteriosklerotiske midler
ES2117976T3 (es) Preparacion de derivados n-acetil neuraminicos.
SE8904354D0 (sv) A pharmaceutical composition
MX9300707A (es) Composiciones liposomaticas topicas que comprenden piroxicam y procedimiento para su preparacion.
MX9301268A (es) Procedimiento para la preparacion de la beta-fenilisoserina y sus analogos y productos obtenidos mediante el mismo.
DE3851362D1 (de) Verfahren zur Herstellung von Cyclooctaamylose.
SE9303853D0 (sv) The use of an ester of inositoltrisphosphate for the preparing of medicaments
NO884523D0 (no) Joderte polymerer, fremgangsmaate for deres fremstilling og deres anvendelse som kontrastmidler.
SE9002342D0 (sv) Medicament
SE7903687L (sv) Cyklohexylkarboxylsyraderivat och sett att framstella desamma
FR2726271B1 (fr) Derives de 6-polyfluoroalcoxy-2-aminobenzothiazole
FI962299A0 (fi) Hirudiinista ja lipofiilisistä yhdisteistä muodostuneet hirudiini-konjugaatit
MX9205385A (es) Perhidro-1-h-pirido(1,2-a)piracinas 2-sustituidas neurolepticas.
ES2122005T3 (es) Medicamento que contiene (-)-metrifonato.
ES542416A0 (es) Procedimiento para preparar glucopiranosidos.
AU1459192A (en) Aminoacyl derivatives of gem-diphosphonic acids, a process for the preparation thereof and pharmaceutical compositions containing them
ES2099658B1 (es) Nuevos derivados de benc(e)indeno, procedimiento de prepararlos, composicion farmaceutica que los contiene, procedimiento de prepararla y utilizacion de aquellos.
AU1466592A (en) Gem-diphosphonic acid nitrosocarbamoyl derivatives, a process for the preparation thereof and pharmaceutical compositions containing them
ES2051876T3 (es) Procedimiento para preparar derivados de la 1-bencenosulfonil-2-oxo-5-alquiltio-pirrolidina.
ES2099973T3 (es) Derivados de ureido-acetamida su preparacion y los medicamentos que los contienen.

Legal Events

Date Code Title Description
NAV Patent application has lapsed

Ref document number: 9101709-5

Format of ref document f/p: F

NAV Patent application has lapsed

Ref document number: 9101709-5

Format of ref document f/p: F